$0.80
2.36% today
Nasdaq, Nov 04, 09:17 pm CET
ISIN
US81750R1023
Symbol
MCRB
Sector
Industry

Seres Therapeutics Inc Target price 2024 - Analyst rating & recommendation

Seres Therapeutics Inc Classifications & Recommendation:

Buy
63%
Hold
13%
Sell
25%

Seres Therapeutics Inc Price Target

Target Price $3.34
Price $0.82
Potential
Number of Estimates 4
4 Analysts have issued a price target Seres Therapeutics Inc 2025 . The average Seres Therapeutics Inc target price is $3.34. This is higher than the current stock price. The highest price target is
$10.00 1,116.69%
register free of charge
, the lowest is .
A rating was issued by 8 analysts: 5 Analysts recommend Seres Therapeutics Inc to buy, 1 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Seres Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Seres Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 126.33 31.00
1,671.81% 75.46%
EBITDA Margin -72.96% -455.10%
97.77% 523.77%
Net Margin -106.82% -383.92%
97.83% 259.40%

5 Analysts have issued a sales forecast Seres Therapeutics Inc 2024 . The average Seres Therapeutics Inc sales estimate is

$31.0m
Unlock
. This is
8,278.38% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$155m 41,791.89%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $126m 1,671.81%
2024
$31.0m 75.46%
Unlock
2025
$14.7m 52.58%
Unlock
2026
$25.0m 70.07%
Unlock
2027
$125m 400.00%
Unlock
2028
$0.0 100.00%
Unlock

2 Analysts have issued an Seres Therapeutics Inc EBITDA forecast 2024. The average Seres Therapeutics Inc EBITDA estimate is

$-141m
Unlock
. This is
7.26% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-136m 10.29%
Unlock
, the lowest is
$-146m 4.23%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-92.2m 60.55%
2024
$-141m 53.07%
Unlock
2025
$-126m 10.34%
Unlock
2026
$-63.6m 49.75%
Unlock

EBITDA Margin

2023 -72.96% 97.77%
2024
-455.10% 523.77%
Unlock
2025
-860.52% 89.08%
Unlock
2026
-254.27% 70.45%
Unlock

6 Seres Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Seres Therapeutics Inc net profit estimate is

$-119m
Unlock
. This is
33.48% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$18.3m 110.20%
Unlock
, the lowest is
$-161m 10.17%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-135m 61.47%
2024
$-119m 11.80%
Unlock
2025
$-83.1m 30.17%
Unlock
2026
$-75.9m 8.65%
Unlock
2027
$-66.4m 12.51%
Unlock
2028
$-128m 93.36%
Unlock

Net Margin

2023 -106.82% 97.83%
2024
-383.92% 259.40%
Unlock
2025
-565.36% 47.26%
Unlock
2026
-303.70% 46.28%
Unlock
2027
-53.14% 82.50%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.89 -0.78
61.47% 12.36%
P/E negative
EV/Sales 9.07

6 Analysts have issued a Seres Therapeutics Inc forecast for earnings per share. The average Seres Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.78
Unlock
. This is
33.90% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$0.12 110.17%
Unlock
, the lowest is
$-1.06 10.17%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.89 61.47%
2024
$-0.78 12.36%
Unlock
2025
$-0.55 29.49%
Unlock
2026
$-0.50 9.09%
Unlock
2027
$-0.44 12.00%
Unlock
2028
$-0.85 93.18%
Unlock

P/E ratio

Current -0.69 37.84%
2024
-1.05 52.17%
Unlock
2025
-1.50 42.86%
Unlock
2026
-1.64 9.33%
Unlock
2027
-1.88 14.63%
Unlock
2028
-0.97 48.40%
Unlock

Based on analysts' sales estimates for 2024, the Seres Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 760.24 61,708.13%
2024
9.07 98.81%
Unlock
2025
19.14 110.88%
Unlock
2026
11.25 41.20%
Unlock
2027
2.25 80.00%
Unlock

P/S ratio

Current 378.08 27,759.49%
2024
4.51 98.81%
Unlock
2025
9.52 110.88%
Unlock
2026
5.60 41.20%
Unlock
2027
1.12 80.00%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today